Yuichiro Amano

Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice

Eriya Kenjo, Hiroyuki Hozumi, Yukimasa Makita et al. · Nature Communications · 2021 · 285 citations · Full text

Life Sciences, Bioengineering, Biotechnology +17

An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)

Michèle Vacca, Ioannis Kamzolas, Lea Mørch Harder et al. · Nature Metabolism · 2024 · 229 citations · Full text

Medicine, Nutrition, Nutritional Sciences +17

Comparative Studies on the Type-B Response Regulators Revealing their Distinctive Properties in the His-to-Asp Phosphorelay Signal Transduction of Arabidopsis thaliana

Yoshinori Tajima, Aya Imamura, Takatoshi Kiba et al. · Plant and Cell Physiology · 2004 · 153 citations · Full text

Life Sciences, Plant Biology, Plant Sciences +15

Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytes

Tomoyuki Nishimoto, Ryuichi Tozawa, Yuichiro Amano et al. · Biochemical Pharmacology · 2003 · 75 citations

Medicine, Biochemistry, Pharmacology +6

Lipid‐lowering properties of TAK‐475, a squalene synthase inhibitor, <i>in vivo</i> and <i>in vitro</i>

Tomoyuki Nishimoto, Yuichiro Amano, Ryuichi Tozawa et al. · British Journal of Pharmacology · 2003 · 73 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +14